MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - December 06, 2011) -
MorphoSys AG /
MorphoSys Unveils Next-Generation Antibody Technology Ylanthia®
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Novel Library Concept to Result in Drug Candidates with Superior
against Unique Targets and Epitopes
MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) today unveiled its
next-generation antibody technology Ylanthia(®). The technology was
presented to an
audience of specialists at the 2011 Antibody Engineering and
Therapeutics Conference in San Diego. MorphoSys expects Ylanthia to
standards for therapeutic antibody generation in the pharmaceutical
over the next decade and beyond. Commercial application will commence in
"Ylanthia takes antibody technology beyond current methods, among
HuCAL platform is perhaps the most successful representative,"
Simon Moroney, Chief Executive Officer of MorphoSys AG. "We believe
success story of therapeutic antibodies can be substantially expanded if
current limitations can be overcome. Ylanthia addresses many issues
limiting the success of this class of drugs. This innovative platform will
up attractive commercial opportunities for us as it delivers a stream
antibody drugs both for ourselves and our partners."
There are two major reasons why existing technologies limit the
development of therapeutic antibodies. First, many antibodies
development due to poor biophysical properties, which render the molecule
developable". If the antibody cannot be manufactured, or its properties
difficult to handle, chances of successful commercialization are slim.
failure to generate antibodies against all regions or "epitopes" of a
lead to highly promising disease targets being overlooked. Lack of
antibody generation means that putative targets often are not
"interrogated" with antibodies intended to probe their role in
processes. The Ylanthia technology was specifically conceived and
overcome these limitations.
Ylanthia comprises a large collection or "library" of human
guiding principle underlying the design and construction of the library
ensure that the library is of the highest possible quality. Features
distinguish Ylanthia from other technologies include:
* Size and heavy/light chain pairing: Ylanthia is the industry's largest
antibody Fab library, comprising over 100 billion distinct, fully human
antibodies. Ylanthia uses 36 fixed, naturally-occurring heavy and light
chain framework combinations, which translates into unprecedented
diversity. Great care was invested into the antigen binding site
library's diversity is expected to result in antibodies against
inaccessible target molecules and unique epitope coverage.
* Biophysical properties: Antibody frameworks were pre-selected for
levels, stability and aggregation behavior. A shift towards higher
and stress tolerance will increase shelf life and serum stability of
resulting antibody products, making them more cost-effective to produce
administer. A higher solubility in turn opens up the path for more
convenient ways of administration, to the benefit of patients.
* Optimization: When needed, antibodies from the Ylanthia library are
optimized using MorphoSys's proprietary Slonomics(®) technology,
MorphoSys obtained through its 2010 acquisition of Sloning
Ylanthia thereby distinguishes itself in a central respect from HuCAL,
relies on a modular gene design and pre-formed cassettes for antibody
optimization. Slonomics enables optimization of Ylanthia antibodies
unprecedented speed and flexibility.
"In Ylanthia, even more than in previous technology generations,
built into the antibody library itself," commented Dr. Marlies Sproll,
Scientific Officer of MorphoSys AG. "By engineering out the very flaws that
to delays in antibody programs, we expect Ylanthia to result in higher
success rates and shorter timelines in antibody drug development. By
unprecedented functional diversity, Ylanthia will allow us to fully
disease targets, to deliver unique drug candidates, and potentially even
re-visit "false negatives" - targets which were overlooked when worked
More information on MorphoSys's new antibody library:
Ylanthia(®) and 100 billion high potentials™ are trademarks of
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipeline of more than 70 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.
regular updates about MorphoSys, visit http://www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®),
CysDisplay(®), RapMAT(®) and
arYla(®) are registered trademarks of MorphoSys AG.
Slonomics(®) is a registered trademark of Sloning BioTechnology
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
Press Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.